We had previously reported that 6-methylene
progesterone, an inhibitor of
5 alpha-reductase, the
enzyme which converts
testosterone to
dihydrotestosterone, markedly inhibited growth of the
androgen-dependent Dunning R3327-H rat prostatic
tumors. We now find that the
progesterone derivatives
melengestrol acetate (MGA) and
megestrol acetate (MA) inhibit both the
androgen-dependent (Dunning R3327-H) and the
androgen-independent (Dunning R3327-AT3) prostatic
tumors. Growth of the AT3
tumors was suppressed by approximately 53% after 9 days of daily s.c.
injections with MGA
at 10 mg/kg
body weight. MGA also caused a 54%
weight reduction of the ventral prostate and a 53% reduction of the seminal vesicles. Adrenal weights were reduced by 42%. A 24-day oral treatment with MGA (at approximately 15-17 mg/(kg.day)) inhibited AT3
tumor growth by 59% and caused a
weight reduction in the following tissues: prostate (46%), seminal vesicles (19%), testes (12%), and adrenals (52%). Under the same protocol, MA inhibited AT3
tumor growth by 32% and reduced the weight of the ventral prostate by 49% and the weight of the adrenals by 18%, but had no effect on the seminal vesicles and testes. The extent of the MGA-induced prostatic regression was accompanied by cytological changes similar to those effected by 6-methylene
progesterone, i.e., shrinking of the acinar epithelium. The AT3
tumors in MGA-treated rats displayed a limited degree of apoptosis.
Atrophy of the adrenal cortex and lowered plasma levels of
corticosterone and dihydroepiandrosterone were also observed. A therapeutic role for MGA and MA against
androgen-independent prostatic neoplasms in man is forecast by these observations.